NCT03789292View on ClinicalTrials.gov

A Study to Compare Efficacy and Safety of CT-P17 With Humira in Patients With Active Rheumatoid Arthritis

PHASE3CompletedINTERVENTIONAL
Enrollment

648

Participants

Timeline

Start Date

November 26, 2018

Primary Completion Date

October 8, 2019

Study Completion Date

April 24, 2020

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

CT-P17 SC

Subcutaneous injection of Adalimumab 40mg every two weeks

BIOLOGICAL

Humira SC

Subcutaneous injection of Adalimumab 40mg every two weeks

Trial Locations (1)

Unknown

National Multiprofile Transport Hospital Tsar Boris III, Sofia

Sponsors

Lead Sponsor

Celltrion
All Listed Sponsors
lead

Celltrion

INDUSTRY

NCT03789292 - A Study to Compare Efficacy and Safety of CT-P17 With Humira in Patients With Active Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter